Cyclopenta[b]pyrrole | 250-36-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Cyclopenta[b]pyrrole
• CAS: 250-36-2
• 化学式: C₇H₅N
• 分子量: 103.12
• InChiKey: YEDVUDDWJVRKIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] COMPOUNDS USEFUL AS CSF1 MODULATORS<br/>[FR] COMPOSÉS UTILES EN TANT QUE MODULATEURS DU FACTEUR 1 DE STIMULATION DE COLONIES
  申请人：REDX PHARMA PLC

  公开号：WO2016051193A1

  公开（公告）日：2016-04-07

  This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

  这项发明涉及新颖化合物以及包含这些新颖化合物的药物组合物。更具体地，该发明涉及用作集落刺激因子1受体（cFMS）调节剂（例如cFMS抑制剂）的化合物。这项发明还涉及制备这些化合物的方法，这些化合物在治疗中的用途以及利用这些化合物进行治疗的方法。具体而言，该发明涉及利用这些化合物治疗癌症和自身免疫性疾病。
• [EN] OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS<br/>[FR] OXAZOLOPYRIMIDINES COMME AGONISTES DU RÉCEPTEUR EDG-1
  申请人：SANOFI AVENTIS

  公开号：WO2010006704A1

  公开（公告）日：2010-01-21

  The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的恶唑并嘧啶化合物，其中A，R1，R2和R3的定义如权利要求所述。式I的化合物能够调节Edg-1受体的活性，特别是作为该受体的激动剂，并且可用于治疗例如动脉粥样硬化、心力衰竭或外周动脉闭塞性疾病等疾病。此外，本发明还涉及制备式I化合物的方法、它们的使用，特别是在药物中的活性成分，以及包含它们的药物组合物。
• CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-d]PYRIMIDINE RING
  申请人：KADEREIT Dieter

  公开号：US20130023544A1

  公开（公告）日：2013-01-24

  The invention therefore relates to compounds of the formula I in which A, X, Y, R 1 , R 2 and R 3 have the given meanings. The compounds of the formula I are suitable, for example, for wound healing.

  因此，该发明涉及具有以下含义的式I的化合物，其中A、X、Y、R1、R2和R3。例如，式I的化合物适用于伤口愈合。
• CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING
  申请人：Kadereit Dieter

  公开号：US20130079357A1

  公开（公告）日：2013-03-28

  The invention relates to oxazolopyrimidine compounds of formula (I), where A, R 1 , R 2 , R 3 , R 4 and X are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

  该发明涉及式(I)的噁唑嘧啶化合物，其中A、R1、R2、R3、R4和X如索权中所述。式(I)的化合物例如适用于伤口愈合。
• Inhibitors of checkpoint kinases
  申请人：Arrington Kenneth L.

  公开号：US20070254879A1

  公开（公告）日：2007-11-01

  The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了包含替代三唑喹唑啉酮的化合物，这些化合物抑制CHK1活性。本发明还提供了包含这种抑制化合物的组合物，以及通过将该化合物给予需要癌症治疗的患者来抑制CHK1活性的方法。